Certara logo
CERTCertara
Trade CERT now
Certara primary media

About Certara

Certara (NASDAQ:CERT) is a global biosimulation company that plays a pivotal role in the acceleration of drug discovery and development. It specializes in creating software and services that support decision-making processes of the biopharmaceutical and healthcare sectors. The company's range of projects encompasses regulatory science, drug development, and the application of quantitative systems pharmacology (QSP) to increase the efficiency and success rate of bringing new therapies to market. Certara's objectives are closely tied to improving human health through innovation, reducing the time and cost associated with drug development, and enhancing decision-making in complex scenarios. This approach not only benefits the pharmaceutical industry but also aims to have a direct positive impact on patient outcomes.

What is CERT known for?

Snapshot

Public US
Ownership
2008
Year founded
1258
Employees
New Jersey, United States
Head office
1 of 5
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
United States

Products and/or services of Certara

  • Biosimulation: Leveraging virtual patient populations and simulations to predict how drugs behave in different demographic groups.
  • Regulatory Science: Providing expertise and software to streamline regulatory submissions and approvals for pharmaceutical products.
  • PBPK Modeling Software: Advanced platforms for physiologically based pharmacokinetic modeling, aiding in drug discovery and development.
  • Quantitative Systems Pharmacology (QSP): Integrating computational modeling and experimental data to explore complex biological systems and drug effects.
  • Market Access and HEOR: Offering evidence-based services to demonstrate product value and support global market access strategies.
  • Clinical Trial Data Services: Utilizing sophisticated software to analyze and manage clinical trial data, optimizing trial outcomes.

Certara executive team

  • Mr. Leif E. PedersenPresident & Chief Commercial Officer
  • Mr. John E. Gallagher IIISVP, Principal Accounting Officer & Chief Financial Officer
  • Dr. Robert P. Aspbury Ph.D.President of Certara Predictive Technologies
  • Mr. Jon ResnickCEO & Director
  • Dr. Christopher Bouton Ph.D.Chief Technology Officer
  • Mr. Daniel D. CorcoranSenior VP & General Counsel
  • Mr. Ron DiSantisSenior Vice President of Corporate Development
  • Ms. Sheila Rocchio MBAChief Marketing Officer
  • Ms. Rona AnhaltChief Human Resources Officer
  • Dr. Frederic Yves Bois Ph.D., Pharm.D.Senior Scientific Advisor, Head of Mechanistic Modeling & Member of Simcyp Advisory Board

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.